Country: United States
Language: English
Source: NLM (National Library of Medicine)
ESOMEPRAZOLE MAGNESIUM (UNII: R6DXU4WAY9) (ESOMEPRAZOLE - UNII:N3PA6559FT)
Sunshine Lake Pharma Co., Ltd.
ORAL
PRESCRIPTION DRUG
Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsule is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsule may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsule is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole magnesium delayed-release capsule is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older. Esomeprazole magnesium delayed-release capsule is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patien
Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, are white or almost white capsules, with “S1” imprinted on the cap of shell, the contents of capsules is white or off-white pellets. They are supplied as follows: NDC 48792-7843-1 bottles of 60 Esomeprazole Magnesium Delayed-Release Capsules USP, 40 mg, are white or almost white capsules, with “S2” imprinted on the cap of shell, the contents of capsules is white or off-white pellets. They are supplied as follows: NDC 48792-7842-1 bottles of 60 Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature]. Keep Esomeprazole Magnesium Delayed-Release Capsules USP container tightly closed. Dispense in a tight container if the Esomeprazole Magnesium Delayed-Release Capsules USP product package is subdivided.
Abbreviated New Drug Application
ESOMEPRAZOLE MAGNESIUM- ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE Sunshine Lake Pharma Co., Ltd. ---------- MEDICATION GUIDE Esomeprazole (ES-oh-MEP-ra-zole) Magnesium (mag-NEE-zee-um) Delayed-Release Capsules Read the Medication Guide that comes with esomeprazole magnesium delayed-release capsules before you start taking esomeprazole magnesium delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. What is the most important information I should know about esomeprazole magnesium delayed-release capsules? Esomeprazole magnesium delayed-release capsules may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor. Esomeprazole magnesium delayed-release capsules can cause serious side effects, including: • A type of kidney problem (acute interstitial nephritis). Some people who take proton pump inhibitor (PPI) medicines, including esomeprazole magnesium delayed-release capsules, may develop a kidney problem called acute interstitial nephritis that can happen at any time during treatment with esomeprazole magnesium delayed-release capsules. Call your doctor if you have a decrease in the amount that you urinate or if you have blood in your urine. • Diarrhea. Esomeprazole magnesium delayed-release capsules may increase your risk of getting severe diarrhea. This diarrhea may be caused by an infection (Clostridium difficile) in your intestines. Call your doctor right away if you have watery stool, stomach pain, and fever that does not go away. • Bone fractures. People who take multiple daily doses of PPI medicines for a long period of time (a year or longer) may have an increased risk of fractures of the hip, wrist, or spine. You should take esomeprazole magnesium delayed-release capsules exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor abou Read the complete document
ESOMEPRAZOLE MAGNESIUM- ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE SUNSHINE LAKE PHARMA CO., LTD. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ESOMEPRAZOLE MAGNESIUM DELAYED- RELEASE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES. ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 1989 (OMEPRAZOLE) RECENT MAJOR CHANGES 1. Warnings and Precautions, Atrophic Gastritis (5.2) removed 10/2016 2. Warnings and Precautions, Cutaneous and Systemic Lupus Erythematosus (5.5) 10/2016 INDICATIONS AND USAGE Esomeprazole magnesium delayed-release capsule is a proton pump inhibitor indicated for the following: Treatment of gastroesophageal reflux disease (GERD). (1.1) Risk reduction of NSAID-associated gastric ulcer. (1.2) _H. pylori _eradication to reduce the risk of duodenal ulcer recurrence. (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. (1.4) DOSAGE AND ADMINISTRATION INDIC ATIO N DO SE FREQUENCY GASTROESOPHAGEAL REFLUX DISEASE (GERD) Adults 20 mg or 40 mg Once daily for 4 to 8 weeks 12 to 17 years 20 mg or 40 mg Once daily for up to 8 weeks 1 to 11 years 10 mg or 20 mg Once daily for up to 8 weeks RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER 20 mg or 40 mg Once daily for up to 6 months _H. PYLORI_ ERADICATION _(Triple Therapy):_ esomeprazole magnesium 40 mg Once daily for 10 days Amoxicillin 1000 mg Twice daily for 10 days Clarithromycin 500 mg Twice daily for 10 days PATHOLOGICAL HYPERSECRETORY CONDITIONS 40 mg Twice daily See full prescribing information for administration options. (2) Patients with severe liver impairment-do not exceed dose of 20 mg. (2) DOSAGE FORMS AND STRENGTHS Esomeprazole Magnesium Delayed-Release Capsules, USP: 20 mg and 40 mg. ( 3) CONTRAINDICATIONS Patients with known hypersensitivity to proton pump inhibitors (PPIs) (angioedema and anaphylaxis have occurred). (4) WARNINGS AND PR Read the complete document